Lisando GmbH

Business Strategies

Recombinant, selective acting (ARTILYSIN®e) antimicrobial proteins engineered and developed by ISO 13485 certified Lisando GmbH to efficiently combat bacterial pathogens. The resulting ARTILYSIN® platform finds application in almost all fields that are under bacterial attack.


- finds particular application combating antibiotic resistant bacteria

- is effective against gram negative bacteria (e.g. Acinetobacter, Salmonella, EHEC, Pseudomonas)

- is effective against gram positive bacteria (e.g. Staphylococcus, Streptococcus)

Core Technologies and Services

Based on the ARTILYSIN® platform, applicable ARTILYSIN® is developed according to customer specifications. ARTILYSIN® acts selectively so that pathogenic target bacteria are foremost eliminated and the microbiome remains intact. The bacteria are lysed via a mechanical, physical mechanism within seconds. ARTILYSIN® is environmentally-friendly, is rapidly biologically degraded and therefore dose not accumulate in the environment. ARTILYSIN® compared to antibiotics is significantly more stable to the development of resistance.

Patent, Licenses, Co-operations

Lisando GmbH distinguishes itself with goal-directed and expeditious work, is punctual and works closely with customers. Lisando GmbH has much experience in working with large concerns and medium-sized companies. The ARTILYSIN® platform is protected by a broad patent portfolio.


Please contact our office directly:  Markus Matuschka v. Greiffenclau

Go back